Tom Borge Johannesen
Overview
Explore the profile of Tom Borge Johannesen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
1773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vener C, Lillini R, De Angelis R, Bonfarnuzzo S, Poirel H, Trama A, et al.
Eur J Cancer
. 2025 Mar;
220:115231.
PMID: 40056559
Background: EUROCARE, a European population-based cancer project, has shown geographical survival disparities for myeloid neoplasms (MN) suggesting healthcare inequalities. Total National Health Expenditure (TNHE) might influence population-based MN survival. We...
2.
Johansson A, Skog A, Johannesen T, Myklebust T, Konig S, Skovlund C, et al.
Acta Oncol
. 2025 Feb;
64:257-266.
PMID: 39935358
Background And Purpose: The COVID-19 pandemic impacted substantially on cancer healthcare, including the temporary suspension of screening activities. We compared cancer incidence rates and stage during 2020-2021 to pre-pandemic rates...
3.
Dahl A, Johannesen T, Gjelsvik Y, Myklebust T, Fossa S
Radiother Oncol
. 2024 Dec;
204:110704.
PMID: 39732292
Background And Purpose: We lack population-based data on the use and effectiveness of phosphodiesterase- 5inhibitors (PDE-5Is) in post-radiotherapy long-term prostate cancer survivors (PCaSs). In this cross-sectional survey performed 9 years...
4.
Nilsson M, Aas K, Myklebust T, Gjelsvik Y, Johannesen T, Fossa S
Clin Genitourin Cancer
. 2024 Sep;
22(6):102219.
PMID: 39340952
Introduction: Studies about adverse health outcomes (AHOs) after radical prostatectomy (RP) in population-based contemporary prostate cancer (PCa) patients are limited, as well as knowledge about corresponding data from age-similar men...
5.
Lundberg F, Ekman S, Johansson A, Engholm G, Birgisson H, Olafsdottir E, et al.
Lung Cancer
. 2024 May;
192:107826.
PMID: 38795460
Objectives: The aim of this study was to evaluate if the previously reported improvements in lung cancer survival were consistent across age at diagnosis and by lung cancer subtypes. Materials...
6.
Blakstad H, Mendoza Mireles E, Kierulf-Vieira K, Singireddy D, Mdala I, Heggebo L, et al.
J Neurooncol
. 2024 May;
169(1):137-145.
PMID: 38762830
Purpose: Glioblastoma (GBM) is an aggressive brain tumor in which primary therapy is standardized and consists of surgery, radiotherapy (RT), and chemotherapy. However, the optimal time from surgery to start...
7.
Fossa S, Storas A, Aas K, Johannesen T, Gjelsvik Y, Myklebust T
Eur Urol Open Sci
. 2024 Apr;
63:62-70.
PMID: 38558766
Background And Objective: Registry-based studies for prostate cancer (PCa) document higher overall mortality (OM) after high-dose radiotherapy (RT) than after radical prostatectomy (RP). Our aim was to explore the association...
8.
Skaga E, Trewin-Nybraten C, Niehusmann P, Johannesen T, Marienhagen K, Oltedal L, et al.
Acta Oncol
. 2024 Mar;
63:83-94.
PMID: 38501768
Background: Surveillance of incidence and survival of central nervous system tumors is essential to monitor disease burden and epidemiological changes, and to allocate health care resources. Here, we describe glioma...
9.
Lundberg F, Birgisson H, Engholm G, Olafsdottir E, Morch L, Johannesen T, et al.
Eur J Cancer
. 2024 Mar;
202:113980.
PMID: 38452724
Background: The survival in patients diagnosed with cutaneous malignant melanoma (CMM) has improved in the Nordic countries in the last decades. It is of interest to know if these improvements...
10.
Blakstad H, Mendoza Mireles E, Heggebo L, Magelssen H, Sprauten M, Johannesen T, et al.
Neurooncol Pract
. 2024 Jan;
11(1):36-45.
PMID: 38222046
Background: Differentiating post-radiation MRI changes from progressive disease (PD) in glioblastoma (GBM) patients represents a major challenge. The clinical problem is two-sided; avoid termination of effective therapy in case of...